Antihypertensive effect of CS-905, a novel dihydropyridine calcium blocker, in conscious hypertensive dogs.
CS-905, (+-)-3-(1-diphenylmethylazetidin-3-yl)5-isopropyl 2-amino-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridine-dicarboxy lat e, is a novel dihydropyridine calcium blocker. Both CS-905 and nicardipine, when administered orally, produced a dose-dependent fall of blood pressure in conscious perinephritic hypertensive dogs. Unlike the hypotensive effect of nicardipine, that of CS-905 has a gradual onset and is long-lasting, with little increase in the heart rate and plasma renin activity (PRA). The lack of both tachycardia and increase of PRA is probably mostly due to the slow onset of antihypertensive action following CS-905.
Biological Research Laboratories, Sankyo Co., Ltd., Tokyo, Japan.
K
K
Oizumi
M
M
Miyamoto
H
H
Koike
D000818:Animals; D000959:Antihypertensive Agents; D001383:Azetidinecarboxylic Acid / Q000031:analogs & derivatives / Q000494:pharmacology*; D001385:Azetines / Q000494:pharmacology*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D004095:Dihydropyridines / Q000494:pharmacology*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D006977:Hypertension, Renal / Q000188:drug therapy / Q000503:physiopathology; D007606:Juxtaglomerular Apparatus / Q000187:drug effects; D008297:Male; D009392:Nephrectomy; D009529:Nicardipine / Q000494:pharmacology; D012083:Renin / Q000097:blood; D012084:Renin-Angiotensin System / Q000187:drug effects
D000959:Antihypertensive Agents; D001385:Azetines; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D001383:Azetidinecarboxylic Acid; D009529:Nicardipine; D012083:Renin; C061679:azelnidipine